Another Outcome Lost to the Benefits of Levosimendan?

Pediatr Crit Care Med. 2019 Oct;20(10):992-994. doi: 10.1097/PCC.0000000000002019.

Authors

Peta M A Alexander¹, Ayse Akcan-Arikan, Lara S Shekerdemian

Affiliation

¹ Department of Cardiology, Boston Children's Hospital; and Department of Pediatrics, Harvard Medical School, Boston, MA Department of Pediatrics, Section of Critical Care Medicine; and Department of Pediatrics, Section of Nephrology, Baylor College of Medicine, Houston, TX Department of Pediatrics, Section of Critical Care Medicine, Baylor College of Medicine, Houston, TX.

PMID: 31580276
DOI: 10.1097/PCC.0000000000002019

No abstract available

Publication types

Editorial
Comment

MeSH terms

Acute Kidney Injury*
Cardiotonic Agents
Heart Defects, Congenital*
Humans
Milrinone
Simendan

Substances

Cardiotonic Agents
Simendan
Milrinone